Clinically Isolated Syndrome of Demyelination
1 clinical trials · Condition
◉ Watch Clinically Isolated Syndrome of Demyelination
| Record | Firm | Date |
|---|---|---|
| Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS) (NCT05418010) | Queen Mary University of London | 2022-12-01 |
Track Clinically Isolated Syndrome of Demyelination automatically
Every clearance here is in the API, with alerts when new ones post.